Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Sponsor: James Graham Brown Cancer Center
Terminated
funding discontinued by sponsor
Other terminated trials from James Graham Brown Cancer Center
Other Carcinoma, Non-Small Cell Lung trials with similar outcome
This PHASE2 trial investigates Carcinoma, Non-Small Cell Lung and Carcinoma, Small Cell Lung and is currently terminated or withdrawn. James Graham Brown Cancer Center leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
May 2017 — Mar 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — May 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- James Graham Brown Cancer Center
- Novartis Pharmaceuticals
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .